• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Deborah Kilpatrick Joins Sonder Capital as its Newest Venture Partner

    10/28/24 7:00:00 AM ET
    $ISRG
    $PRCT
    $SNBR
    $SWAV
    Industrial Specialties
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ISRG alert in real time by email

    SAN CARLOS, Calif., Oct. 28, 2024 /PRNewswire/ -- Sonder Capital, a leading healthcare venture firm focused on innovative technologies ushering in a new standard of care in medicine, announced the addition of Deborah Kilpatrick, Ph.D., former CEO of Evidation Health and co-founder of MedtechWomen, as a Venture Partner.

    Sonder Capital

    Kilpatrick earned her Ph.D. from Georgia Tech in mechanical engineering with a focus in bioengineering and a minor in applied mathematics. Most recently, she was the CEO and Executive Chair of the Board at Evidation Health, a technology company that pioneered the use of person-generated health data and connected devices in decentralized research and large-scale health programs. Prior to Evidation, Kilpatrick held leadership roles in medical device and molecular diagnostic companies, including multiple roles at Guidant Corporation such as Research Fellow, Director of Research and Technology Development, and Director of New Ventures, prior to its acquisition by Boston Scientific. She is the co-Founder of MedtechWomen and the MedtechVision Conference, held annually in Silicon Valley and currently serves on the Board of Directors at Sleep Number (NASDAQ:SNBR), NextGen Jane, and Sutter Health, one of the largest and most innovative healthcare systems in the US providing care to millions throughout California.

    Kilpatrick's background in medical devices coupled with her expertise in digital health technology will strengthen the Sonder team's ability to navigate and identify future investments in the medtech sector as it rapidly evolves to integrate multi-modal health data and AI.

    "I'm excited to join the Sonder team and be a part of creating what's next in medtech," said Kilpatrick. "There is no doubt that the sector has driven better patient outcomes for decades. But I believe medtech is entering a new era where novel technologies will drive entirely new standards of care and transform both the clinician and patient experience in ways we are just beginning to imagine."

    "We couldn't be more excited to welcome Deb to the Sonder team," said Kate Garrett, Managing Partner of Sonder Capital. "The future of the medtech industry will become a convergence of big data, AI and connected devices, creating unprecedented opportunities to improve healthcare. With a career deeply rooted in all of these areas, Deb brings unparalleled expertise to our team. Beyond that, Deb has been a champion of women leaders in the healthcare sector her entire career, something I and thousands of others have benefitted from. We are thrilled to be working side by side with her."

    About Sonder Capital

    Sonder's team of veteran investors, innovators, founder-operators, and company builders is known not only for their individual achievements, but also for their collective success in creating, funding, and leading private and public companies that have transformed healthcare for millions of patients globally — including Intuitive Surgical (NASDAQ:ISRG), Shockwave Medical (NASDAQ:SWAV), Procept Biorobotics (NASDAQ:PRCT), Auris Health, and Reflexion Medical, among others. Sonder's extensive network of limited partners is global and includes industry leaders, high-net-worth individuals, and leading family offices focused on investing in game-changing healthcare technologies. Sonder Capital was co-founded in 2019 by healthcare luminaries Jay Watkins and Fred Moll, M.D

    Contacts

    Marisa Meehan, Sonder Capital

    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/deborah-kilpatrick-joins-sonder-capital-as-its-newest-venture-partner-302288301.html

    SOURCE Sonder Capital

    Get the next $ISRG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • Who has been appointed as the new Venture Partner at Sonder Capital?

      Deborah Kilpatrick has joined Sonder Capital as a Venture Partner, bringing extensive experience in healthcare technology and leadership roles in the medtech sector.

    • What was Deborah Kilpatrick's previous role before joining Sonder Capital?

      Kilpatrick was previously the CEO of Evidation Health, where she led efforts in utilizing person-generated health data and connected devices for research and health programs.

    • What is Deborah Kilpatrick's educational background?

      Kilpatrick holds a Ph.D. in mechanical engineering with a focus on bioengineering from Georgia Tech and has been involved in various leadership roles in medical device companies, including Guidant Corporation.

    • Why is Deborah Kilpatrick's addition significant for Sonder Capital?

      Joining Sonder Capital enhances their investment capabilities in the rapidly evolving medtech sector, especially in areas integrating multi-modal health data and AI.

    • What vision did Deborah Kilpatrick express about the future of the medtech sector?

      Kilpatrick emphasized that medtech is entering a new era where innovative technologies will set new standards of care and significantly enhance patient and clinician experiences.

    Recent Analyst Ratings for
    $ISRG
    $PRCT
    $SNBR
    $SWAV

    CompanyDatePrice TargetRatingAnalyst
    Intuitive Surgical Inc.
    $ISRG
    3/11/2026$590.00Neutral → Buy
    Citigroup
    PROCEPT BioRobotics Corporation
    $PRCT
    3/6/2026$30.00Neutral
    Robert W. Baird
    PROCEPT BioRobotics Corporation
    $PRCT
    2/26/2026Outperform → Perform
    Oppenheimer
    PROCEPT BioRobotics Corporation
    $PRCT
    2/26/2026$20.00Neutral → Underperform
    BofA Securities
    Intuitive Surgical Inc.
    $ISRG
    1/27/2026$660.00Buy
    TD Cowen
    PROCEPT BioRobotics Corporation
    $PRCT
    12/12/2025$62.00Buy
    UBS
    Intuitive Surgical Inc.
    $ISRG
    12/11/2025$635.00Buy → Neutral
    Citigroup
    PROCEPT BioRobotics Corporation
    $PRCT
    12/8/2025$38.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $ISRG
    $PRCT
    $SNBR
    $SWAV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Desai Antal Rohit bought $10,482,943 worth of shares (426,262 units at $24.59) (SEC Form 4)

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    3/9/26 7:19:42 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Director Moll Frederic H bought $785,138 worth of shares (20,000 units at $39.26), increasing direct ownership by 2% to 863,159 units (SEC Form 4)

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    8/14/25 4:18:26 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Interim CFO Ryder Robert P bought $102,160 worth of shares (15,000 units at $6.81) (SEC Form 4)

    4 - Sleep Number Corp (0000827187) (Issuer)

    8/4/25 4:05:05 PM ET
    $SNBR
    Home Furnishings
    Consumer Discretionary

    $ISRG
    $PRCT
    $SNBR
    $SWAV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ISRG
    $PRCT
    $SNBR
    $SWAV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ISRG
    $PRCT
    $SNBR
    $SWAV
    SEC Filings

    View All

    $ISRG
    $PRCT
    $SNBR
    $SWAV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sonder Capital Closes its Second Fund and Announces Participation from Major Healthcare Systems

    SAN CARLOS, Calif., March 24, 2026 /PRNewswire/ -- Sonder Capital, a healthcare venture capital firm investing in companies revolutionizing the standard of care, today announced the closing of its second fund, Futures II. The fund includes participation from Mayo Clinic and Sutter Health, reflecting their collective interest in innovative technologies that have the potential to advance the future of patient care by enhancing access, improving quality and transforming the overall patient experience."Through our second fund we'll continue enabling the next wave of companies and he

    3/24/26 11:03:00 AM ET
    $ISRG
    $PRCT
    $SWAV
    Industrial Specialties
    Health Care
    Medical/Dental Instruments

    Sleep Number's New, Innovative Product Line Available in Stores and Online Today

    Continued Strong Sales Momentum for ComfortMode™ Signals Consumer Appetite for Enhanced Comfort, Adjustability, Temperature Benefits and Value Launches Simplified Web Experience that Makes Shopping Easier for Customers Sleep Number Corporation (NASDAQ:SNBR) today announced that its redesigned mattress portfolio is now available for purchase nationwide in Sleep Number® stores and at SleepNumber.com. The launch follows strong early demand for ComfortMode™, the first bed introduced as part of the company's largest product reset in almost a decade. Sleep Number also introduced an improved, simplified web experience designed to help customers more easily explore the portfolio and find the ri

    3/23/26 9:00:00 AM ET
    $SNBR
    Home Furnishings
    Consumer Discretionary

    EAU Guidelines Upgrade Aquablation® Therapy to Strong Surgical Recommendation for BPH

    SAN JOSE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (NASDAQ:PRCT) today highlighted the latest update to the European Association of Urology (EAU) Guidelines for male lower urinary tract symptoms (LUTS), which include an upgrade of Aquablation therapy to a strong recommendation as a surgical treatment option for men with benign prostatic hyperplasia (BPH). The EAU guidelines are widely regarded as one of the most rigorous and influential clinical guideline frameworks in urology globally. The updated guidelines now strongly recommend offering Aquablation therapy as an alternative to transurethral resection of the prostate (TURP) for men with moderate-to-severe urinary

    3/23/26 7:00:00 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Nouri Alaleh

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    3/19/26 5:47:08 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Nouri Alaleh

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    3/19/26 4:25:58 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Waters Kevin

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    3/19/26 4:25:16 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Sleep Number Corporation

    SCHEDULE 13G/A - Sleep Number Corp (0000827187) (Subject)

    3/27/26 4:16:49 PM ET
    $SNBR
    Home Furnishings
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13G/A filed by Sleep Number Corporation

    SCHEDULE 13G/A - Sleep Number Corp (0000827187) (Subject)

    3/27/26 1:19:58 PM ET
    $SNBR
    Home Furnishings
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13G/A filed by PROCEPT BioRobotics Corporation

    SCHEDULE 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

    3/27/26 11:20:49 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Intuitive Surgical upgraded by Citigroup with a new price target

    Citigroup upgraded Intuitive Surgical from Neutral to Buy and set a new price target of $590.00

    3/11/26 8:28:54 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    Robert W. Baird initiated coverage on PROCEPT BioRobotics with a new price target

    Robert W. Baird initiated coverage of PROCEPT BioRobotics with a rating of Neutral and set a new price target of $30.00

    3/6/26 8:35:41 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics downgraded by Oppenheimer

    Oppenheimer downgraded PROCEPT BioRobotics from Outperform to Perform

    2/26/26 7:23:22 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $ISRG
    $PRCT
    $SNBR
    $SWAV
    Financials

    Live finance-specific insights

    View All

    Sleep Number Announces Fourth Quarter and Full Year 2025 Results

    Reports FY2025 Net Sales of $1.4 Billion, Exceeding Adjusted EBITDA Guidance Realized $185 Million of Annualized Cost Savings Launches New Products as the Next Phase of Turnaround Strategy to Return to Profitable Growth Sleep Number Corporation (NASDAQ:SNBR) today reported results for fourth quarter and the year ended January 3, 2026. Linda Findley, President and CEO, commented, "Sleep Number exceeded 2025 guidance provided on our last earnings call. We are still in full turnaround mode and made significant progress against our new product and marketing strategies while continuing to reduce costs. For the full year 2025, pro-forma adjusted EBITDA margin was approximately 9% and anti

    3/12/26 7:00:00 AM ET
    $SNBR
    Home Furnishings
    Consumer Discretionary

    Sleep Number Corporation to Announce Fourth Quarter and Full Year 2025 Results on March 12, 2026

    Sleep Number Corporation (NASDAQ:SNBR) will release its fiscal fourth quarter and full year results through January 3, 2026, before market open on Thursday, March 12, 2026. Management will host its regularly scheduled conference call to discuss the company's results at 8:30 a.m. EDT (7:30 a.m. CDT; 5:30 a.m. PDT). To access the webcast, please visit the investor relations area of the Sleep Number website at ir.sleepnumber.com. The webcast replay will remain available for approximately 60 days. About Sleep Number Corporation Sleep Number® is the leader in personalized sleep wellness. Its mattresses are designed to evolve with each sleeper to help them feel and perform their best. With

    3/3/26 4:34:00 PM ET
    $SNBR
    Home Furnishings
    Consumer Discretionary

    PROCEPT BioRobotics Reports Fourth Quarter 2025 Financial Results and Updates 2026 Revenue Guidance

    SAN JOSE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended December 31, 2025. "In the fourth quarter, we delivered our highest procedure volume to date—approximately 12,200—and sold 65 new systems, marking our strongest capital quarter," said Larry Wood, Chief Executive Officer. "At the same time, we took meaningful steps to position the Company for its next phase of growth. To sharpen our focus on delivering durable procedure growth, we realigned our commer

    2/25/26 4:02:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $ISRG
    $PRCT
    $SNBR
    $SWAV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Sleep Number Corporation

    SC 13D/A - Sleep Number Corp (0000827187) (Subject)

    12/2/24 5:07:30 PM ET
    $SNBR
    Home Furnishings
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Sleep Number Corporation

    SC 13D/A - Sleep Number Corp (0000827187) (Subject)

    11/25/24 6:54:27 PM ET
    $SNBR
    Home Furnishings
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation

    SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

    11/14/24 1:28:32 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $ISRG
    $PRCT
    $SNBR
    $SWAV
    Leadership Updates

    Live Leadership Updates

    View All

    Sleep Number Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    Sleep Number Corporation (NASDAQ:SNBR) today announced that it granted equity awards on March 16, 2026, as a material inducement to the employment of the company's Executive Vice President and Chief Financial Officer, Amy O'Keefe. As previously disclosed, in connection with the appointment of O'Keefe as Executive Vice President and Chief Financial Officer effective December 8, 2025, Sleep Number agreed to grant O'Keefe employment inducement awards on or around March 15, 2026. The equity awards granted on March 16, 2026 pursuant to that agreement consist of: (i) 66,965 shares of common stock underlying a time-vested restricted stock unit award, vesting in three equal installments on each a

    3/16/26 4:00:00 PM ET
    $SNBR
    Home Furnishings
    Consumer Discretionary

    Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the appointment of Maria Sainz to its Board of Directors effective as of January 9, 2026. "We are delighted to welcome Maria to our Board of Directors," said Pulse Biosciences' Co-Chairman of the Board Robert W. Duggan. "She brings an exceptionally strong track record of guiding both public and private medical device companies through growth, commercialization, viability, and scale. Her strategic and operational expertise will be invaluable as Pulse begins creating and disrupting interventional m

    1/9/26 7:00:00 AM ET
    $AVNS
    $HYPR
    $OFIX
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    Sleep Number Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Sleep Number Corporation (NASDAQ:SNBR) today announced that it granted an equity award on December 15, 2025, as a material inducement to the employment of the company's newly-hired Executive Vice President and Chief Financial Officer, Amy O'Keefe. As previously disclosed, in connection with the appointment of O'Keefe as Executive Vice President and Chief Financial Officer effective December 8, 2025, Sleep Number granted O'Keefe an employment inducement award consisting of 69,742 shares in a time-vested restricted stock unit award that vests in three equal installments on each anniversary from the date of grant. The grants are subject to continued employment and the terms of the award agree

    12/15/25 4:01:00 PM ET
    $SNBR
    Home Furnishings
    Consumer Discretionary